Tag: license

BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- FloBiotech today announced an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in neurodegeneration.

HOUSTON, June 09, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced that the Baobab field on CI-40 block, offshore Côte d’Ivoire is back online following the successful Baobab Ivoirien Floating Production Storage and Offloading vessel (“FPSO”) refurbishment.

GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, has appointed Sachin Chawla to the new position of senior vice president, strategy and growth.

He will direct and manage the company’s business development, sales and marketing activities, while helping the CEO advance M&A and broader business growth initiatives in support of the company’s strategic growth plan.

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio^® (vedolizumab) lyophilized vial for intravenous administration.

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-III” or the “Company”) today reported results for the first quarter of fiscal year 2027, ended April 30, 2026.